{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:48:55Z","timestamp":1794325735025,"version":"4.9.0"},"reference-count":26,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The primary and prespecified updated analyses of ICARIA-MM (clinicaltrial gov. Identifier: NCT02990338) demonstrated improved progression-free survival (PFS) and a benefit in overall survival (OS) was reported with the addition of isatuximab, an anti-CD38 monoclonal antibody, to pomalidomide-dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma. Here, we report the final OS analysis. This multicenter, randomized, open-label, phase III study included patients who had received and failed \u22652 previous therapies, including lenalidomide and a proteasome inhibitor. Between January 10, 2017, and February 2, 2018, 307 patients were randomized (1:1) to isatuximab-pomalidomide-dexamethasone (Isa-Pd; N=154) or Pd (N=153), stratified based on age (&lt;75 vs. \u226575 years) and number of previous lines of therapy (2-3 vs. &gt;3). At data cutoff for the final OS analysis after 220 OS events (January 27, 2022), median follow-up duration was 52.4 months. Median OS was 24.6 months (95% confidence interval [CI]: 20.3-31.3) with Isa-Pd and 17.7 months (95% CI: 14.4- 26.2) with Pd (hazard ratio=0.78; 95% CI: 0.59-1.02; 1-sided P=0.0319). Despite subsequent daratumumab use in the Pd group and its potential benefit on PFS in the first subsequent therapy line, median PFS2 was significantly longer with Isa-Pd versus Pd (17.5 vs. 12.9 months; log-rank 1-sided P=0.0091). In this analysis, Isa-Pd continued to be efficacious and well tolerated after follow-up of approximately 52 months, contributing to a clinically meaningful, 6.9-month improvement in median OS in patients with relapsed\/refractory multiple myeloma.<\/jats:p>","DOI":"10.3324\/haematol.2023.284325","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:38:04Z","timestamp":1706765884000},"page":"2239-2249","source":"Crossref","is-referenced-by-count":17,"title":["Isatuximab-pomalidomide-dexamethasone &lt;i&gt;versus&lt;\/i&gt; pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis"],"prefix":"10.3324","volume":"109","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus San","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Mac\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mony Chenda","family":"Morisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"63526","doi-asserted-by":"crossref","unstructured":"Abramson HN. The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets. Clin Lymphoma Myeloma Leuk. 2018; 18(9):611-627.","DOI":"10.1016\/j.clml.2018.06.015"},{"key":"63527","doi-asserted-by":"crossref","unstructured":"Legarda MA, Cejalvo MJ, de la Rubia J. Recent advances in the treatment of patients with multiple myeloma. Cancers (Basel). 2020; 12(12):3576.","DOI":"10.3390\/cancers12123576"},{"key":"63528","doi-asserted-by":"crossref","unstructured":"Ninkovic S, Quach H. Shaping the treatment paradigm based on the current understanding of the pathobiology of multiple myeloma: an overview. Cancers (Basel). 2020; 12(11):3488.","DOI":"10.3390\/cancers12113488"},{"key":"63529","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020; 10(9):94.","DOI":"10.1038\/s41408-020-00359-2"},{"key":"63530","doi-asserted-by":"crossref","unstructured":"Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016; 51(4):479-491.","DOI":"10.1038\/bmt.2015.307"},{"key":"63531","doi-asserted-by":"crossref","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018; 131(1):13-29.","DOI":"10.1182\/blood-2017-06-740944"},{"key":"63532","doi-asserted-by":"crossref","unstructured":"Munshi C, Aarhus R, Graeff R, Walseth TF, Levitt D, Lee HC. Identification of the enzymatic active site of CD38 by site-directed mutagenesis. J Biol Chem. 2000; 275(28):21566-21571.","DOI":"10.1074\/jbc.M909365199"},{"key":"63533","doi-asserted-by":"crossref","unstructured":"Malavasi F, Deaglio S, Funaro A. Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology. Physiol Rev. 2008; 88(3):841-886.","DOI":"10.1152\/physrev.00035.2007"},{"key":"63534","doi-asserted-by":"crossref","unstructured":"Chillemi A, Quarona V, Antonioli L, Ferrari D, Horenstein AL, Malavasi F. Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche. Front Immunol. 2017; 8:305.","DOI":"10.3389\/fimmu.2017.00305"},{"key":"63535","doi-asserted-by":"crossref","unstructured":"Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016; 30(2):399-408.","DOI":"10.1038\/leu.2015.240"},{"key":"63536","unstructured":"Sanofi. SARCLISA [Package Insert]. 2021. Publisher Full Text|"},{"key":"63537","doi-asserted-by":"crossref","unstructured":"Tai YT, Anderson KC. Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget. 2017; 8(68):112166-112167.","DOI":"10.18632\/oncotarget.22992"},{"key":"63538","doi-asserted-by":"crossref","unstructured":"Attal M, Richardson PG, Rajkumar SV. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394(10214):2096-2107.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"63539","doi-asserted-by":"crossref","unstructured":"Richardson PG, Perrot A, San-Miguel J. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022; 23(3):416-427.","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"63540","unstructured":"European Medicines Agency. Sarclisa. 2023. Publisher Full Text|"},{"key":"63541","doi-asserted-by":"crossref","unstructured":"Richardson PG, Attal M, Campana F. Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/ dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018; 14(11):1035-1047.","DOI":"10.2217\/fon-2017-0616"},{"key":"63542","doi-asserted-by":"crossref","unstructured":"Mikhael J, Belhadj-Merzoug K, Hulin C. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021; 11(5):89.","DOI":"10.1038\/s41408-021-00478-4"},{"key":"63543","doi-asserted-by":"crossref","unstructured":"Wang J, Lv C, Zhou M, Xu JY, Chen B, Wan Y. Second primary malignancy risk in multiple myeloma from 1975 to 2018. Cancers (Basel). 2022; 14(19):4919.","DOI":"10.3390\/cancers14194919"},{"key":"63544","doi-asserted-by":"crossref","unstructured":"Musto P, Anderson KC, Attal M. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017; 28(2):228-245.","DOI":"10.1093\/annonc\/mdw606"},{"key":"63545","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S. Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023; 41(3):568-578.","DOI":"10.1200\/JCO.21.02815"},{"key":"63546","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018; 379(19):1811-1822.","DOI":"10.1056\/NEJMoa1805762"},{"key":"63547","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M. Subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM): overall survival results from the phase 3 Apollo Study. Blood. 2022; 140(Suppl 1):7272-7274.","DOI":"10.1182\/blood-2022-163483"},{"key":"63548","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Beksac M. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(6):781-794.","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"63549","doi-asserted-by":"crossref","unstructured":"Beksac M, Richardson P, Oriol A. Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial. Clin Lymphoma Myeloma Leuk. 2023; 23:S27-S28.","DOI":"10.1016\/S2152-2650(23)01611-7"},{"key":"63550","doi-asserted-by":"crossref","unstructured":"Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2016; 27(3):373-378.","DOI":"10.1093\/annonc\/mdv562"},{"key":"63551","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284325\/76593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284325\/77197","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11432\/76593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:37Z","timestamp":1794045937000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284325","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}